Myelodysplastic Syndrome – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Myelodysplastic Syndrome – Pipeline Review, H2 2016’, provides an overview of the Myelodysplastic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome

The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects

The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Acceleron Pharma Inc

Actinium Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

Altor BioScience Corp

Amgen Inc

Apogenix GmbH

Ariad Pharmaceuticals Inc

Arno Therapeutics Inc

Arog Pharmaceuticals Inc

Array BioPharma Inc

Astex Pharmaceuticals Inc

Atara Biotherapeutics Inc

Bellicum Pharmaceuticals Inc

BerGenBio AS

Bio-Path Holdings Inc

BioLineRx Ltd

BioLite Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Cantex Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellerant Therapeutics Inc

Celyad SA

Constellation Pharmaceuticals Inc

Cornerstone Pharmaceuticals Inc

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

DiNonA Inc.

Eisai Co Ltd

Eleos Inc

Eli Lilly and Company

EpiZyme Inc

F. Hoffmann-La Roche Ltd

FORMA Therapeutics Inc

Fujifilm Corp

Gamida Cell Ltd

GlaxoSmithKline Plc

H3 Biomedicine Inc

IGF Oncology LLC

ImmunoGen Inc

Incyte Corp

Io Therapeutics Inc

Jazz Pharmaceuticals Plc

Jiangsu Hansoh Pharmaceutical Co Ltd

Johnson & Johnson

Johnson & Johnson Pharmaceutical Research & Development,

Juno Therapeutics Inc

JW Pharmaceutical Corp

Kainos Medicine Inc

KaloBios Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kyowa Hakko Kirin Co Ltd

La Jolla Pharmaceutical Company

Lixte Biotechnology Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

medac GmbH

MedImmune LLC

MEI Pharma Inc

Merck & Co Inc

Merus NV

Mesoblast Ltd

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Nemucore Medical Innovations Inc

Novartis AG

Onconova Therapeutics Inc

OncoTherapy Science Inc

Opsona Therapeutics Ltd

Pfizer Inc

Pharma Mar SA

Regen BioPharma Inc

Rich Pharmaceuticals Inc

Seattle Genetics Inc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sunesis Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

Targazyme Inc

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Ltd

Toko Pharmaceutical Industries Co., Ltd.

Tolero Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Trillium Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Myelodysplastic Syndrome Overview 8

Therapeutics Development 9

Myelodysplastic Syndrome - Therapeutics under Development by Companies 11

Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 18

Myelodysplastic Syndrome - Pipeline Products Glance 20

Myelodysplastic Syndrome - Products under Development by Companies 24

Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 34

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 35

Myelodysplastic Syndrome - Therapeutics Assessment 131

Drug Profiles 153

Myelodysplastic Syndrome - Dormant Projects 709

Myelodysplastic Syndrome - Discontinued Products 716

Myelodysplastic Syndrome - Product Development Milestones 718

Appendix 730

List of Tables

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H2 2016 27

Number of Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H2 2016 28

Number of Products under Development by Companies, H2 2016 29

Number of Products under Development by Companies, H2 2016 (Contd..1) 30

Number of Products under Development by Companies, H2 2016 (Contd..2) 31

Number of Products under Development by Companies, H2 2016 (Contd..3) 32

Number of Products under Development by Companies, H2 2016 (Contd..4) 33

Number of Products under Development by Companies, H2 2016 (Contd..5) 34

Number of Products under Development by Companies, H2 2016 (Contd..6) 35

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Comparative Analysis by Late Stage Development, H2 2016 38

Comparative Analysis by Clinical Stage Development, H2 2016 39

Comparative Analysis by Early Stage Development, H2 2016 40

Comparative Analysis by Unknown Stage Development, H2 2016 41

Products under Development by Companies, H2 2016 42

Products under Development by Companies, H2 2016 (Contd..1) 43

Products under Development by Companies, H2 2016 (Contd..2) 44

Products under Development by Companies, H2 2016 (Contd..3) 45

Products under Development by Companies, H2 2016 (Contd..4) 46

Products under Development by Companies, H2 2016 (Contd..5) 47

Products under Development by Companies, H2 2016 (Contd..6) 48

Products under Development by Companies, H2 2016 (Contd..7) 49

Products under Development by Companies, H2 2016 (Contd..8) 50

Products under Development by Companies, H2 2016 (Contd..9) 51

Products under Investigation by Universities/Institutes, H2 2016 52

Myelodysplastic Syndrome – Pipeline by 4SC AG, H2 2016 53

Myelodysplastic Syndrome – Pipeline by AbbVie Inc, H2 2016 54

Myelodysplastic Syndrome – Pipeline by Acceleron Pharma Inc, H2 2016 55

Myelodysplastic Syndrome – Pipeline by Actinium Pharmaceuticals Inc, H2 2016 56

Myelodysplastic Syndrome – Pipeline by Aeglea BioTherapeutics Inc, H2 2016 57

Myelodysplastic Syndrome – Pipeline by Agios Pharmaceuticals Inc, H2 2016 58

Myelodysplastic Syndrome – Pipeline by Aileron Therapeutics Inc, H2 2016 59

Myelodysplastic Syndrome – Pipeline by Altor BioScience Corp, H2 2016 60

Myelodysplastic Syndrome – Pipeline by Amgen Inc, H2 2016 61

Myelodysplastic Syndrome – Pipeline by Apogenix GmbH, H2 2016 62

Myelodysplastic Syndrome – Pipeline by Ariad Pharmaceuticals Inc, H2 2016 63

Myelodysplastic Syndrome – Pipeline by Arno Therapeutics Inc, H2 2016 64

Myelodysplastic Syndrome – Pipeline by Arog Pharmaceuticals Inc, H2 2016 65

Myelodysplastic Syndrome – Pipeline by Array BioPharma Inc, H2 2016 66

Myelodysplastic Syndrome – Pipeline by Astex Pharmaceuticals Inc, H2 2016 67

Myelodysplastic Syndrome – Pipeline by Atara Biotherapeutics Inc, H2 2016 68

Myelodysplastic Syndrome – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 69

Myelodysplastic Syndrome – Pipeline by BerGenBio AS, H2 2016 70

Myelodysplastic Syndrome – Pipeline by Bio-Path Holdings Inc, H2 2016 71

Myelodysplastic Syndrome – Pipeline by BioLineRx Ltd, H2 2016 72

Myelodysplastic Syndrome – Pipeline by BioLite Inc, H2 2016 73

Myelodysplastic Syndrome – Pipeline by Boehringer Ingelheim GmbH, H2 2016 74

Myelodysplastic Syndrome – Pipeline by Boston Biomedical Inc, H2 2016 75

Myelodysplastic Syndrome – Pipeline by Bristol-Myers Squibb Company, H2 2016 76

Myelodysplastic Syndrome – Pipeline by Cantex Pharmaceuticals Inc, H2 2016 77

Myelodysplastic Syndrome – Pipeline by Celgene Corp, H2 2016 78

Myelodysplastic Syndrome – Pipeline by Celldex Therapeutics Inc, H2 2016 79

Myelodysplastic Syndrome – Pipeline by Cellerant Therapeutics Inc, H2 2016 80

Myelodysplastic Syndrome – Pipeline by Celyad SA, H2 2016 81

Myelodysplastic Syndrome – Pipeline by Constellation Pharmaceuticals Inc, H2 2016 82

Myelodysplastic Syndrome – Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 83

Myelodysplastic Syndrome – Pipeline by CrystalGenomics Inc, H2 2016 84

Myelodysplastic Syndrome – Pipeline by CTI BioPharma Corp, H2 2016 85

Myelodysplastic Syndrome – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 86

Myelodysplastic Syndrome – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 87

Myelodysplastic Syndrome – Pipeline by DiNonA Inc., H2 2016 88

Myelodysplastic Syndrome – Pipeline by Eisai Co Ltd, H2 2016 89

Myelodysplastic Syndrome – Pipeline by Eleos Inc, H2 2016 90

Myelodysplastic Syndrome – Pipeline by Eli Lilly and Company, H2 2016 91

Myelodysplastic Syndrome – Pipeline by EpiZyme Inc, H2 2016 92

Myelodysplastic Syndrome – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 93

Myelodysplastic Syndrome – Pipeline by FORMA Therapeutics Inc, H2 2016 94

Myelodysplastic Syndrome – Pipeline by Fujifilm Corp, H2 2016 95

Myelodysplastic Syndrome – Pipeline by Gamida Cell Ltd, H2 2016 96

Myelodysplastic Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2016 97

Myelodysplastic Syndrome – Pipeline by H3 Biomedicine Inc, H2 2016 98

Myelodysplastic Syndrome – Pipeline by IGF Oncology LLC, H2 2016 99

Myelodysplastic Syndrome – Pipeline by ImmunoGen Inc, H2 2016 100

Myelodysplastic Syndrome – Pipeline by Incyte Corp, H2 2016 101

Myelodysplastic Syndrome – Pipeline by Io Therapeutics Inc, H2 2016 102

Myelodysplastic Syndrome – Pipeline by Jazz Pharmaceuticals Plc, H2 2016 103

Myelodysplastic Syndrome – Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 104

Myelodysplastic Syndrome – Pipeline by Johnson & Johnson, H2 2016 105

Myelodysplastic Syndrome – Pipeline by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H2 2016 106

Myelodysplastic Syndrome – Pipeline by Juno Therapeutics Inc, H2 2016 107

Myelodysplastic Syndrome – Pipeline by JW Pharmaceutical Corp, H2 2016 108

Myelodysplastic Syndrome – Pipeline by Kainos Medicine Inc, H2 2016 109

Myelodysplastic Syndrome – Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 110

Myelodysplastic Syndrome – Pipeline by Karyopharm Therapeutics Inc, H2 2016 111

Myelodysplastic Syndrome – Pipeline by Kiadis Pharma NV, H2 2016 112

Myelodysplastic Syndrome – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 113

Myelodysplastic Syndrome – Pipeline by La Jolla Pharmaceutical Company, H2 2016 114

Myelodysplastic Syndrome – Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 115

Myelodysplastic Syndrome – Pipeline by MacroGenics Inc, H2 2016 116

Myelodysplastic Syndrome – Pipeline by Mateon Therapeutics Inc, H2 2016 117

Myelodysplastic Syndrome – Pipeline by medac GmbH, H2 2016 118

Myelodysplastic Syndrome – Pipeline by MedImmune LLC, H2 2016 119

Myelodysplastic Syndrome – Pipeline by MEI Pharma Inc, H2 2016 120

Myelodysplastic Syndrome – Pipeline by Merck & Co Inc, H2 2016 121

Myelodysplastic Syndrome – Pipeline by Merus NV, H2 2016 122

Myelodysplastic Syndrome – Pipeline by Mesoblast Ltd, H2 2016 123

Myelodysplastic Syndrome – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 124

Myelodysplastic Syndrome – Pipeline by Mirati Therapeutics Inc, H2 2016 125

Myelodysplastic Syndrome – Pipeline by Nemucore Medical Innovations Inc, H2 2016 126

Myelodysplastic Syndrome – Pipeline by Novartis AG, H2 2016 127

Myelodysplastic Syndrome – Pipeline by Onconova Therapeutics Inc, H2 2016 128

Myelodysplastic Syndrome – Pipeline by OncoTherapy Science Inc, H2 2016 129

Myelodysplastic Syndrome – Pipeline by Opsona Therapeutics Ltd, H2 2016 130

Myelodysplastic Syndrome – Pipeline by Pfizer Inc, H2 2016 131

Myelodysplastic Syndrome – Pipeline by Pharma Mar SA, H2 2016 132

Myelodysplastic Syndrome – Pipeline by Regen BioPharma Inc, H2 2016 133

Myelodysplastic Syndrome – Pipeline by Rich Pharmaceuticals Inc, H2 2016 134

Myelodysplastic Syndrome – Pipeline by Seattle Genetics Inc, H2 2016 135

Myelodysplastic Syndrome – Pipeline by Stemline Therapeutics Inc, H2 2016 136

Myelodysplastic Syndrome – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 137

Myelodysplastic Syndrome – Pipeline by Sunesis Pharmaceuticals Inc, H2 2016 138

Myelodysplastic Syndrome – Pipeline by Syndax Pharmaceuticals Inc, H2 2016 139

Myelodysplastic Syndrome – Pipeline by Takara Bio Inc, H2 2016 140

Myelodysplastic Syndrome – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 141

Myelodysplastic Syndrome – Pipeline by Targazyme Inc, H2 2016 142

Myelodysplastic Syndrome – Pipeline by TetraLogic Pharmaceuticals, H2 2016 143

Myelodysplastic Syndrome – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 144

Myelodysplastic Syndrome – Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016 145

Myelodysplastic Syndrome – Pipeline by Tolero Pharmaceuticals Inc, H2 2016 146

Myelodysplastic Syndrome – Pipeline by Tragara Pharmaceuticals Inc, H2 2016 147

Myelodysplastic Syndrome – Pipeline by Trillium Therapeutics Inc, H2 2016 148

Assessment by Monotherapy Products, H2 2016 149

Assessment by Combination Products, H2 2016 150

Number of Products by Stage and Target, H2 2016 152

Number of Products by Stage and Mechanism of Action, H2 2016 160

Number of Products by Stage and Route of Administration, H2 2016 168

Number of Products by Stage and Molecule Type, H2 2016 170

Myelodysplastic Syndrome – Dormant Projects, H2 2016 727

Myelodysplastic Syndrome – Dormant Projects (Contd..1), H2 2016 728

Myelodysplastic Syndrome – Dormant Projects (Contd..2), H2 2016 729

Myelodysplastic Syndrome – Dormant Projects (Contd..3), H2 2016 730

Myelodysplastic Syndrome – Dormant Projects (Contd..4), H2 2016 731

Myelodysplastic Syndrome – Dormant Projects (Contd..5), H2 2016 732

Myelodysplastic Syndrome – Dormant Projects (Contd..6), H2 2016 733

Myelodysplastic Syndrome – Discontinued Products, H2 2016 734

Myelodysplastic Syndrome – Discontinued Products (Contd..1), H2 2016 735

List of Figures

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H2 2016 27

Number of Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H2 2016 28

Number of Products under Development by Companies, H2 2016 29

Number of Products under Investigation by Universities/Institutes, H2 2016 36

Comparative Analysis by Clinical Stage Development, H2 2016 39

Comparative Analysis by Early Stage Products, H2 2016 40

Assessment by Monotherapy Products, H2 2016 149

Number of Products by Top 10 Targets, H2 2016 151

Number of Products by Stage and Top 10 Targets, H2 2016 151

Number of Products by Top 10 Mechanism of Actions, H2 2016 159

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 159

Number of Products by Routes of Administration, H2 2016 167

Number of Products by Stage and Routes of Administration, H2 2016 167

Number of Products by Top 10 Molecule Types, H2 2016 169

Number of Products by Stage and Top 10 Molecule Types, H2 2016 169

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports